Abstract
Tenofovir (PMPA) is a novel nucleotide analog that belongs to the class of acyclic nucleoside phosphonates. The potential antiviral effect of tenofovir was demonstrated by Hol and DeClercq (Balzarini et al., 1993). In this class of compounds, the ribose-phosphate group is replaced with the isopolar phosphonopropyl ether functionality. Tenofovir is recognized by host kinases and is phosphorylated in situ to the virologically active tenofovir diphosphate. Tenofovir diphosphate inhibits the human immunodeficiency virus (HIV-1 and HIV-2) DNA polymerase (reverse transcriptase) in addition to other viral DNA polymerases (Naesens et al., 1997). This inhibition results in DNA chain termination and impairment of viral replication. The IC50 values of tenofovir inhibition of HIV-1 reverse transcriptase is between 0.04 and 8.5 µM (Viread package insert).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Arimilli M, Kim C, and Bischofberger N. Synthesis, In Vitro Biological Evaluation and Oral Bioavailability of 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) Prodrugs. Antivir Chem Chemother 1997; 8:557–564
Balzarini J, Holý A, Jindrich J, Naesens L, Snoeck R, Schols D, and De Clercq E. Differential Antiherpesvirus and Antiretrovirus Effects of the (S) and (R) Enantiomers of Acyclic Nucleoside Phosphonates: Potent and Selective In Vitro and In Vivo Antiretrovirus Activities of (R)-9-(2-Propyl)-2,6-diaminopurine. Antimicrob Agents Chemother 1993; 37:332–338
Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, Kearney BP, Coleman RL, Lamy PD, Kahn JO, McGowan I, and Lietman PS. Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in HIV-1 Infected Adults. Antimicrob Agents Chemother. 2001; 45:2733–2739
Cundy KC. Clinical Anti-HIV Activity of Tenofovir Disoproxil Fumarate Correlates with Intracellular Drug Levels (Abstract 318). 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon, Portugal, 1999. Poster 318
Cundy KC, Sueoka CM, Lynch GR, Griffin L, Lee WA, and Shaw J-P. Pharmacokinetics and Bioavailability of the Anti-human Immunodeficiency Virus Nucleotide Analog 9-[(R)-2-(Phosphonomethoxy)propyl]adenine (PMPA) in Dogs. Antimicrob Agents Chemother 1998; 42:687–690
Deeks SG, Barditch-Crovo P, Lietman PS, Hwang K, Cundy C, Rooney JF, Hellmann NS, Safrin S, and Kahn JO. Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-(R)-(Phosphonomethoxy)propyl] adenine, A Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected Adults. Antimicrob Agents Chemother 1998; 42:2380–2384
Flaherty JF, Kearney BP, Wolf JJ, Sayre JR, and Coakley DF. A Multiple-Dose, Randomized, Crossover Drug Interaction Study between Tenofovir DF and Efavirenz, Indinavir, or Lopinavir/Ritonavir [Poster]. The 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001, Poster Number 336
Kearney BP, Flaherty JF, Sayre JR, Wolf JJ, and Coakley DF. A Multiple-Dose, Randomized, Crossover Drug Interaction Study between Tenofovir DF and Lamivudine or Didanosine. The 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001, Poster Number 337
Margot NA, Johnson A, Cheng A, Coakley DF, and Miller MD. Final 48-Week Genotypic and Phenotypic Analyses of Study 907: Tenofovir DF (TDF) Added to Stable Background Regimens [poster abstract]. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA 2002
Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, and De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and Related Acyclic Nucleoside Phosphonate Analogues: A Review of their Pharmacology and Clinical Potential in the Treatment of Viral Infections. Antivir Chem Chemother 1997; 8:1–23
Naesens L, Bischofberger N, Augustijns P, Annaert P, Van den Mooter G, M. Arimilli N, Kim CU, and De Clercq E Antiretroviral Efficacy and Pharmacokinetics of Oral Bis(isopropyloxycarbonyloxymethyl)-9(2-phosphonylmethoxypropyl) Adenine in Mice. Antimicrob Agents Chemother 1998; 42:1568–1573
Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen S-S, Miller MD, Isaacson E, and Cheng AK. Tenofovir DF in Antiretroviral-experienced Patients: Results from a 48-week, Randomized, Double-blind Study. AIDS. 2002; 16:1257–1263
Shaw J-P, Sueoka CM, Oliyai R, Lee WA, Arimilli MN, Kim CU, and Cundy KC. Metabolism and Pharmacokinetics of Novel Oral Prodrugs of 9-[(R)-2-(Phosphonomethoxy)propyl]adenine (PMPA) in Dogs. Pharm Res 1997; 14:1824–1829
Sigel H. Metal Ion Complexes of Antivirally Active Nucleotide Analogues. Conclusions Regarding their Biological Action. Chem Soc Rev 2004; 33:191–200
Squires K, Pierone G, Berger D, Steinhart C, Bellos N, Becker SL, Chen SS, Miller MD, Coakley DF, and Cheng A. Tenofovir DF: A 48-week Final Analysis from a Phase III Randomized, Double Blind, Placebo Controlled Study in Antiretroviral Experienced Patients (Study 907). In: Programs and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002 Poster Abstract 413-W
VIREAD® (tenofovir disoproxil fumarate) Tablets. Package Insert. Gilead Sciences, Inc. Foster City, CA. June 2004
Yuan L-C, Dahl TC, and Oliyai R. Effect of Carbonate Salts on the Kinetics of Acid-catalyzed Dimerization of Adefovir Dipivoxil. Pharm Res 2000; 17:1098–1103
Yuan L-C, Dahl TC, and Oliyai R. Degradation Kinetics of Oxycarbonyloxymethyl Prodrugs of Phosphonates in Solution. Pharm Res 2001; 18:234–237
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Fardis, M., Oliyai, R. (2007). Case Study: Tenofovir Disoproxil Fumarate: An Oral Prodrug of Tenofovir. In: Stella, V.J., Borchardt, R.T., Hageman, M.J., Oliyai, R., Maag, H., Tilley, J.W. (eds) Prodrugs. Biotechnology: Pharmaceutical Aspects, vol V. Springer, New York, NY. https://doi.org/10.1007/978-0-387-49785-3_52
Download citation
DOI: https://doi.org/10.1007/978-0-387-49785-3_52
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-49782-2
Online ISBN: 978-0-387-49785-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)